Academic Journal
Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease
| العنوان: | Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease |
|---|---|
| المؤلفون: | Laura H. Gunn, Ailsa J. McKay, Amy Feng, Michael J. Louie, Christie M. Ballantyne, Kausik K. Ray |
| المصدر: | Atherosclerosis Plus, Vol 49, Iss , Pp 20-27 (2022) |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2022 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Cardiovascular disease, lipid-lowering drugs, secondary prevention, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| الوصف: | Background and aims: Cardiovascular outcomes trials have demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk for future cardiovascular events. We assessed the potential cardiovascular benefits of bempedoic acid through a simulation study in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated LDL-C. Methods: The validated SMART prediction model was used to estimate the baseline 10-year risk of three-point major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in patients with ASCVD who were enrolled in four Phase 3, randomized, placebo-controlled bempedoic acid studies. The predicted change in 10-year cardiovascular risk associated with bempedoic acid was estimated for each patient based on the Cholesterol Treatment Trialists’ model. Data were analyzed in two cohorts: Cohort 1 included mostly patients treated with moderate-high intensity statins, and Cohort 2 included patients who were intolerant of more than low-intensity statin. Results: A total of 2884 patients were included in Cohort 1 and 226 in Cohort 2. Weighted average baseline 10-year cardiovascular event risk was 26.1% and 31.6% for Cohorts 1 and 2, respectively. The least squares mean percent difference (95% confidence interval (CI) of the predicted absolute change in 10-year cardiovascular event risk with bempedoic acid was −3.3% (−3.7% to −2.9%) for patients in Cohort 1 and -6.0% (−7.7% to −4.3%) for patients in Cohort 2 compared with placebo (p < 0.0001 for both). Conclusions: Among patients with ASCVD who could potentially benefit from additional LDL-C lowering, our simulation predicted a lower absolute cardiovascular event risk after initiating bempedoic acid as compared with placebo. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2667-0895 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2667089522000153; https://doaj.org/toc/2667-0895; https://doaj.org/article/f6587704d18d43d495fcf411a405f384 |
| DOI: | 10.1016/j.athplu.2022.05.003 |
| الاتاحة: | https://doi.org/10.1016/j.athplu.2022.05.003 https://doaj.org/article/f6587704d18d43d495fcf411a405f384 |
| رقم الانضمام: | edsbas.49E00A75 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 26670895 |
|---|---|
| DOI: | 10.1016/j.athplu.2022.05.003 |